Monopar Presents Promising uPAR Clinical Dosimetry Data at EANM 2024

Monopar Therapeutics Inc., a clinical-stage radiopharmaceutical company, is showcasing significant findings from their lead radiopharmaceutical program, MNPR-101, during the European Association of Nuclear Medicine (EANM) 2024 Annual Congress in Hamburg, Germany. This presentation highlights both clinical and preclinical development data, emphasizing the potential of MNPR-101 in cancer treatment.

MNPR-101's radiation dosimetry analytics, which utilized human data from MNPR-101-Zr, have revealed a promising safety profile for major organs, even at high Lu-177 therapeutic dose levels. The data, presented in a top-rated oral presentation, supports the potential of targeting the urokinase plasminogen activator receptor (uPAR) in solid tumors. This receptor is showing significant promise as a target for radiopharmaceuticals.

The presentation detailed the favorable biodistribution and tumor uptake characteristics of Monopar’s uPAR-targeted radiopharmaceuticals, MNPR-101-Zr and MNPR-101-Lu. The findings from both preclinical and clinical studies show minimal off-target binding, which is crucial for reducing side effects. Andrew Cittadine, Chief Operating Officer of Monopar, noted the successful optimization of these radiopharmaceuticals in preclinical studies. He mentioned that the effort put into these optimizations has paid off, as reflected in the encouraging tumor uptake observed in human subjects.

Further details about Monopar's ongoing research can be found on ClinicalTrials.gov. The MNPR-101-Lu Phase 1a trial is listed under the identifier NCT06617169, and the MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial is under identifier NCT06337084.

Monopar Therapeutics focuses on developing innovative treatments for cancer patients. Their pipeline includes the MNPR-101-Zr for imaging advanced cancers, MNPR-101-Lu in Phase 1a for treatment, and MNPR-101-Ac225 in late preclinical stages. Additionally, the company is working on early development-stage radiopharma programs against solid tumors. Monopar aims to advance cancer treatment through their cutting-edge radiopharmaceutical research, offering hope for more effective and safer cancer therapies.

In summary, Monopar Therapeutics' latest data presentation at the EANM 2024 Annual Congress has highlighted the potential of their uPAR-targeted radiopharmaceuticals. These findings suggest that MNPR-101-Zr and MNPR-101-Lu could become valuable tools in the fight against solid tumors, providing a favorable safety profile and effective tumor targeting. The company's ongoing trials and research continue to push the boundaries of cancer treatment, aiming to bring innovative solutions to patients in need.